Rocket One shares close at $0.4493 as HT-001 developments remain unverified
Key Facts
Rocket One shares, trading under the ticker RKTO, closed at $0.4493 on November 2, 2026, according to EL7 data. The price comes amid a draft report about developments in HT-001, but no reliable open source could verify that the company ended the Phase 2a trial early or confirm interim efficacy results. A plan to move to a pivotal Phase 3 study could not be verified either. These developments therefore cannot be presented as a confirmed announcement of trial progress or a move to a new phase. The share-price movement cited here is dated to the session before the news and is not attributed to an announcement that could not be verified.
EL7 data show the closing price fell from $0.5373 on October 27 to $0.4493 on November 2, 2026. This shows the comparison between the closes on those two dates, without establishing the reason for the change. The draft's reported trading range for the November 2 session could not be verified: neither its low nor high was confirmed by a reliable open source or the EL7 data provided. The closing price remains the market data available for that session in the evidence. Any link between the share performance and HT-001 developments therefore remains unconfirmed.
The drug program traces its roots to Hoth Therapeutics, which changed its name to Rocket One Inc. on May 26, 2026, according to its quarterly report filed with the U.S. Securities and Exchange Commission. The report says Hoth Therapeutics LLC is a wholly owned subsidiary. It also describes HT-001 as a topical formulation under development to treat side effects caused by drugs used to treat cancer. The company's website describes the drug as a topical gel targeting skin toxicities associated with EGFR inhibitor cancer treatments. The website says the Phase 2a study is still recruiting at sites in the United States, the study status documented by the available source.
In an announcement dated April 1, 2026, Hoth said an interim analysis showed patients had reached an ARIGA score of no more than 1 by week six. The company added that a pharmacokinetic analysis showed approximately 99% lower systemic exposure compared with FDA-approved oral treatments. These results remain attributed to the company's announcement on that date and do not in themselves confirm the later report that the trial ended early. In its annual report, Hoth said it was recruiting participants in both study cohorts: open-label and randomized, double-blind. This provides earlier context on the study design and recruitment efforts, without confirming a change in its status or the announcement of final results.
On geographic expansion, Hoth said in its annual report that it received European Medicines Agency approval in January 2026 to continue the study in Spain, Poland and Hungary. The company then announced on April 1, 2026, that it had received regulatory approval in Hungary to expand the Phase 2 trial into Europe, and said it expected additional approvals in Spain and Poland. These details provide background on the regulatory path the company announced earlier in the year. The next development that can be substantiated from the evidence is the recruiting status listed on the company's website, alongside the approvals and expectations in its earlier announcements. An early termination announcement, a Phase 3 plan or a specific subsequent date could not be verified.